TY - JOUR
T1 - Incidence and Predictors of Complications After Transcatheter Aortic Valve Implantation According to VARC-3 Criteria
T2 - A Systematic Review and Meta-Analysis
AU - Giacobbe, Federico
AU - Bruno, Francesco
AU - Brero, Marco
AU - Meynet, Pierre
AU - Solano, Andrea
AU - Capoccia, Sergio
AU - Pilia, Riccardo
AU - D’Ascenzo, Fabrizio
AU - Conrotto, Federico
AU - Tarantini, Giuseppe
AU - la Torre, Michele
AU - Kim, Won Keun
AU - Buono, Andrea
AU - Blumenstein, Johannes
AU - Polzin, Amin
AU - Gennari, Marco
AU - Gmeiner, Jonas M.D.
AU - Piperata, Antonio
AU - Ruge, Hendrik
AU - Li, Jie
AU - Mascherbauer, Julia
AU - Waksman, Ron
AU - Barbash, Israel
AU - Tang, Gilbert
AU - Gasior, Tomasz
AU - Webb, John
AU - Hioki, Hirofumi
AU - Obaid, Daniel
AU - Mangieri, Antonio
AU - Crimi, Gabriele
AU - Joner, Michael
AU - Toggweiler, Stefan
AU - Mauri, Victor
AU - Lin, Mao Shin
AU - Haussig, Stephan
AU - Avvedimento, Marisa
AU - Nanayakkara, Shane
AU - Serruys, Patrick W.
AU - Landolff, Quentin
AU - Latib, Azeem
AU - Rodes-Cabau, Josep
AU - De Ferrari, Gaetano Maria
AU - de Filippo, Ovidio
N1 - Publisher Copyright:
© 2026 The Author(s). Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
PY - 2026/9
Y1 - 2026/9
N2 - BACKGROUND: Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC-3 criteria to better classify procedural complications. METHODS: We conducted a systematic review and meta-analysis of studies reporting transcatheter aortic valve implantation-related complications using VARC-3 definitions between 2021 and 2025. The primary end point was all-cause mortality at latest follow-up. Secondary end points included major VARC-3 complications and predictors of adverse events. RESULTS: A total of 57 studies with 73588 patients were included. The cohort had a mean age of 81.7years, 51.7% were women, and most had preserved ejection fraction (55.5%) and low-to-moderate surgical risk (Society of Thoracic Surgeons [STS] predicted risk of mortality [PROM] 4.1%). Technical and 30-day device success rates were 95% and 90%, respectively; early safety rate at 30days was 66%. At average 12months follow-up, all-cause mortality was 10.2%. The most common complication was permanent pacemaker implantation (13%), followed by type 2 or greater bleeding (9.7%), acute kidney injury stage 3–4 (4.7%), major vascular events (4.3%), and stroke (3.0%). Moderate/severe paravalvular regurgitation and patient-prosthesis mismatch occurred in 4% and 8%, respectively. Study-level pooled predictor analyses showed that acute kidney injury, type 2 or greater bleeding, paravalvular regurgitation, non-structural valve dysfunction, and higher STS score were associated with higher mortality, while eccentric/severe aortic valve calcification was associated with significant paravalvular regurgitation. CONCLUSIONS: Transcatheter aortic valve implantation shows high procedural success but non-negligible complication rates under VARC-3 criteria. acute kidney injury, type 2 or greater bleeding, NSVD, periprocedural stroke and myocardial infarction after transcatheter aortic valve implantation were associated with higher mortality.
AB - BACKGROUND: Despite continuous advancements in devices and techniques, transcatheter aortic valve implantation remains associated with complications impacting outcomes. In 2021, the Valve Academic Research Consortium (VARC) introduced the VARC-3 criteria to better classify procedural complications. METHODS: We conducted a systematic review and meta-analysis of studies reporting transcatheter aortic valve implantation-related complications using VARC-3 definitions between 2021 and 2025. The primary end point was all-cause mortality at latest follow-up. Secondary end points included major VARC-3 complications and predictors of adverse events. RESULTS: A total of 57 studies with 73588 patients were included. The cohort had a mean age of 81.7years, 51.7% were women, and most had preserved ejection fraction (55.5%) and low-to-moderate surgical risk (Society of Thoracic Surgeons [STS] predicted risk of mortality [PROM] 4.1%). Technical and 30-day device success rates were 95% and 90%, respectively; early safety rate at 30days was 66%. At average 12months follow-up, all-cause mortality was 10.2%. The most common complication was permanent pacemaker implantation (13%), followed by type 2 or greater bleeding (9.7%), acute kidney injury stage 3–4 (4.7%), major vascular events (4.3%), and stroke (3.0%). Moderate/severe paravalvular regurgitation and patient-prosthesis mismatch occurred in 4% and 8%, respectively. Study-level pooled predictor analyses showed that acute kidney injury, type 2 or greater bleeding, paravalvular regurgitation, non-structural valve dysfunction, and higher STS score were associated with higher mortality, while eccentric/severe aortic valve calcification was associated with significant paravalvular regurgitation. CONCLUSIONS: Transcatheter aortic valve implantation shows high procedural success but non-negligible complication rates under VARC-3 criteria. acute kidney injury, type 2 or greater bleeding, NSVD, periprocedural stroke and myocardial infarction after transcatheter aortic valve implantation were associated with higher mortality.
KW - adverse events
KW - complications
KW - predictors
KW - TAVI
KW - transcatheter aortic valve implantation
KW - Valve Academic Research Consortium-3
KW - VARC-3
UR - https://www.scopus.com/pages/publications/105052955122
U2 - 10.1161/JAHA.125.045455
DO - 10.1161/JAHA.125.045455
M3 - Journal article
C2 - 42808440
AN - SCOPUS:105052955122
SN - 2047-9980
VL - 15
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 19
M1 - e045455
ER -